Sepsis (severe) - drotrecogin

Summary

Drotrecogin alfa (activated) is recommended for adult patients who

• have severe sepsis that has resulted in multiple organ failure (two or more major organs are not working properly) and
• are being given the most appropriate intensive care support for their condition.

The use of drotrecogin alfa (activated) should be started and supervised by a specialist consultant with skills in intensive care and experience in the care of patients with sepsis.

Documents

For healthcare professionals

• TA84 Sepsis (severe) - drotrecogin: Quick reference guide
• TA84 Sepsis (severe) - drotrecogin: Guidance
• TA84 Sepsis (severe) - drotrecogin: Guidance (Word version)

For patients, carers and the public

• TA84 Sepsis (severe) - drotrecogin: Information for the public

Background information

• Review decision - March 2008
• Review proposal - December 2007
• Matrix of consultees and commentators
• Sepsis (severe) - drotrecogin: a systematic review and economic evaluation (excluding commercial in confidence data)
• TA84 Sepsis (severe) - drotrecogin: Distribution list
• 2004/039 NICE publishes guidance on the use of drotrecogin alfa (activated) for severe sepsis

Implementing this guidance

Any further information NICE has produced to help the NHS implement this guideline locally is linked to below:

• None found